TrialDiabetes, obesity & metabolism2020

iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan-L study.

Nicola Morea et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.